Background: We hypothesized that the antitumor effects of
asiaticoside on
breast cancer are driven by its ability to decrease the expression of
tumor inflammation-promoting genes and increase apoptotic signaling. In this study, we aimed to better understand the mechanisms of action of
asiaticoside as a chemical modulator or as a chemopreventive agent in
breast cancer. Methods: MCF-7 cells were cultured and treated with 0, 20, 40, and 80 μM
asiaticoside for 48 h. Fluorometric
caspase-9, apoptosis, and gene expression analyses were conducted. For the xenograft experiments, we divided nude mice into the following 5 groups (10 animals per group): group I, control mice; group II, untreated
tumor-bearing nude mice; group III,
tumor-bearing nude mice treated with
asiaticoside at weeks 1-2 and 4-7 and injected with MCF-7 cells at week 3; group IV,
tumor-bearing nude mice injected with MCF-7 cells at week 3 and treated with
asiaticoside beginning at week 6; and group V, nude mice treated with
asiaticoside, as a drug control.
After treatment, weight measurements were performed weekly.
Tumor growth was determined and analyzed using histology and
DNA and
RNA isolation. Results: In MCF-7 cells, we found that
asiaticoside increased
caspase-9 activity. In the xenograft experiment, we found that TNF-α and
IL-6 expression decreased (p < 0.001) via the NF-κB pathway. Conclusion: Overall, our data suggest that
asiaticoside produces promising effects on
tumor growth, progression, and
tumor-associated
inflammation in MCF-7 cells as well as a nude mouse MCF-7
tumor xenograft model.